{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:31:45Z","timestamp":1789774305580,"version":"4.0.1"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.addr.2023.115005","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T21:05:02Z","timestamp":1688591102000},"page":"115005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["A new era in posterior segment ocular drug delivery: Translation of systemic, cell-targeted, dendrimer-based therapies"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3712-7836","authenticated-orcid":false,"given":"Rangaramanujam M.","family":"Kannan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal S.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2023.115005_b0005","unstructured":"W.H. Organization, World report on vision, Geneva, 2019."},{"issue":"9","key":"10.1016\/j.addr.2023.115005_b0010","first-page":"959","article-title":"Visual Function, Social Position, and Health and Life Chances: The UK Biobank Study, JAMA","volume":"134","author":"P.M. Cumberland, J.S. Rahi, f.t.U.B. Eye, V. Consortium","year":"2016","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0015","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/geronb\/gbr015","article-title":"Visual impairment and quality of life among older adults: an examination of explanations for the relationship, The journals of gerontology","volume":"66","author":"Brown","year":"2011","journal-title":"Series B, Psychological sciences and social sciences"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/bjo.2004.047498","article-title":"Impact of unilateral and bilateral vision loss on quality of life","volume":"89","author":"Vu","year":"2005","journal-title":"Br. J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0025","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ophtha.2015.04.014","article-title":"The Global Burden of Potential Productivity Loss from Uncorrected Presbyopia","volume":"122","author":"Frick","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.115005_b0030","doi-asserted-by":"crossref","unstructured":"S.R. Lord, Visual risk factors for falls in older people, Age Ageing 35 Suppl 2 (2006) ii42-ii45.","DOI":"10.1093\/ageing\/afl085"},{"key":"10.1016\/j.addr.2023.115005_b0035","unstructured":"M. Bowen, D.F. Edgar, B. Hancock, S. Haque, R. Shah, S. Buchanan, S. Iliffe, S. Maskell, J. Pickett, J.P. Taylor, N. O\u2019Leary, Health Services and Delivery Research, The Prevalence of Visual Impairment in People with Dementia (the PrOVIDe study): a cross-sectional study of people aged 60\u201389 years with dementia and qualitative exploration of individual, carer and professional perspectives, NIHR Journals Library."},{"key":"10.1016\/j.addr.2023.115005_b0040","unstructured":"Copyright \u00a9 Queen\u2019s Printer and Controller of HMSO 2016. This work was produced by Bowen et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK., Southampton (UK), 2016."},{"issue":"12","key":"10.1016\/j.addr.2023.115005_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob. Health"},{"issue":"9","key":"10.1016\/j.addr.2023.115005_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(17)30293-0","article-title":"Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis","volume":"5","author":"Bourne","year":"2017","journal-title":"Lancet Glob. Health"},{"issue":"10","key":"10.1016\/j.addr.2023.115005_b0055","first-page":"1492","article-title":"Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia: Systematic Review","volume":"125","author":"Fricke","year":"2018","journal-title":"Meta-analysis, and Modelling, Ophthalmology"},{"issue":"11","key":"10.1016\/j.addr.2023.115005_b0060","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.addr.2023.115005_b0065","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"issue":"6","key":"10.1016\/j.addr.2023.115005_b0070","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMcp2102061","article-title":"Age-Related Macular Degeneration","volume":"385","author":"Apte","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjophthalmol-2020-318452","article-title":"Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions","volume":"106","author":"Cabral de Guimaraes","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.addr.2023.115005_b0080","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","author":"Li","year":"2020","journal-title":"Cochrane Database of Systematic Reviews (5)"},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b0085","doi-asserted-by":"crossref","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic Retinopathy Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.addr.2023.115005_b0090","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ophtha.2022.02.021","article-title":"Long-term Outcomes from the HORIZON Randomized Trial for a Schlemm's Canal Microstent in Combination Cataract and Glaucoma Surgery","volume":"129","author":"Ahmed","year":"2022","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0095","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","article-title":"Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use","volume":"144","author":"Robin","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.addr.2023.115005_b0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ophtha.2008.09.004","article-title":"Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study","volume":"116","author":"Okeke","year":"2009","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0105","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41433-019-0665-y","article-title":"Eye drop technique and patient-reported problems in a real-world population of eye drop users","volume":"34","author":"Mehuys","year":"2020","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00003088-200241030-00004","article-title":"Clinical pharmacokinetics of dorzolamide","volume":"41","author":"Martens-Lobenhoffer","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0115","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1755-3768.1979.tb00504.x","article-title":"Tear flow in normal human eyes. Determination by means of radioisotope and gamma camera","volume":"57","author":"S\u00f8rensen","year":"1979","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0120","doi-asserted-by":"crossref","first-page":"NP83-NP86","DOI":"10.1177\/11206721211019548","article-title":"A case of endophthalmitis following needling procedure after PRESERFLO((R)) Micro Shunt implantation","volume":"32","author":"Brambati","year":"2022","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"10.1016\/j.addr.2023.115005_b0125","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/bjophthalmol-2015-307060","article-title":"Severe adverse events associated with local anaesthesia in cataract surgery: 1 year national survey of practice and complications in the UK","volume":"100","author":"Lee","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0130","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.oret.2019.03.023","article-title":"Real-World Trends in Intravitreal Injection Practices among American Retina Specialists","volume":"3","author":"Chaturvedi","year":"2019","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"10.1016\/j.addr.2023.115005_b0135","first-page":"599","volume":"4","author":"Thomson","year":"2009","journal-title":"The promise of nanomedicine for ocular disease"},{"key":"10.1016\/j.addr.2023.115005_b0140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.addr.2017.09.008","article-title":"Overcoming ocular drug delivery barriers through the use of physical forces","volume":"126","author":"Huang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"46","key":"10.1016\/j.addr.2023.115005_b0145","doi-asserted-by":"crossref","first-page":"27835","DOI":"10.1039\/D0RA04971A","article-title":"Nanocarriers for ocular drug delivery: current status and translational opportunity","volume":"10","author":"Gorantla","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.addr.2023.115005_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114770","article-title":"Polymer- and lipid-based nanocarriers for ocular drug delivery: Current status and future perspectives","volume":"196","author":"Han","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.addr.2023.115005_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091931","article-title":"Ocular Drug Delivery: Advancements and Innovations","volume":"14","author":"Tian","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40123-020-00257-7","article-title":"Therapies Based on Nanoparticles for Eye Drug Delivery","volume":"9","author":"Meza-Rios","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b0165","article-title":"Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery, Nanomaterials (Basel","volume":"11","author":"Khiev","year":"2021","journal-title":"Switzerland)"},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b0170","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12951-022-01567-7","article-title":"Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update","volume":"20","author":"Afarid","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2023.115005_b0175","doi-asserted-by":"crossref","unstructured":"X. Bai, J. Wang, Q. Mu, G. Su, In vivo Protein Corona Formation: Characterizations, Effects on Engineered Nanoparticles\u2019 Biobehaviors, and Applications, 9 (2021).","DOI":"10.3389\/fbioe.2021.646708"},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0180","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.drudis.2019.05.006","article-title":"Therapeutic implications of nanomedicine for ocular drug delivery","volume":"24","author":"Meng","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"14","key":"10.1016\/j.addr.2023.115005_b0185","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.addr.2005.09.004","article-title":"Topical and systemic drug delivery to the posterior segments","volume":"57","author":"Hughes","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115005_b0190","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jconrel.2020.10.028","article-title":"Ocular barriers to retinal delivery of intravitreal liposomes: Impact of vitreoretinal interface","volume":"328","author":"Tavakoli","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2023.115005_b0195","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2018.03.001","article-title":"The suprachoroidal space as a route of administration to the posterior segment of the eye","volume":"126","author":"Chiang","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0200","first-page":"e10246","volume":"6","author":"Anselmo","year":"2021","journal-title":"Nanoparticles in the clinic: An update post COVID-19 vaccines"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0205","first-page":"e10143","volume":"4","author":"Anselmo","year":"2019","journal-title":"Nanoparticles in the clinic: An update"},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b0210","first-page":"10","volume":"1","author":"Anselmo","year":"2016","journal-title":"Nanoparticles in the clinic"},{"key":"10.1016\/j.addr.2023.115005_b0215","doi-asserted-by":"crossref","unstructured":"S. Soares, J. Sousa, A. Pais, C. Vitorino, Nanomedicine: Principles, Properties, and Regulatory Issues, 6 (2018).","DOI":"10.3389\/fchem.2018.00360"},{"issue":"12","key":"10.1016\/j.addr.2023.115005_b0220","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00210-022-02287-3","article-title":"Nanomedicine and drug delivery to the retina: current status and implications for gene therapy","volume":"395","author":"Tawfik","year":"2022","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"5","key":"10.1016\/j.addr.2023.115005_b0225","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1167\/iovs.13-12660","article-title":"Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study","volume":"55","author":"Sheppard","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b0230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcrs.2008.09.024","article-title":"Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain","volume":"35","author":"Korenfeld","year":"2009","journal-title":"J Cataract Refract Surg"},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0235","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0240","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur J Ophthalmol"},{"issue":"9","key":"10.1016\/j.addr.2023.115005_b0245","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease","volume":"126","author":"Goldberg","year":"2019","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.addr.2023.115005_b0250","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/ICO.0000000000001989","article-title":"Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b\/3 and Phase 3 Studies","volume":"38","author":"Malhotra","year":"2019","journal-title":"Cornea"},{"issue":"14","key":"10.1016\/j.addr.2023.115005_b0255","article-title":"The Effect of Cyclokat\u00ae (preservative-free cyclosporine 0.1% cationic emulsion) on Dry Eye Disease Signs and Symptoms in Sjogren and non-Sjogren Patients with Moderate to Severe DED in a Phase III Randomized Clinical Trial","volume":"53","author":"Buggage","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2023.115005_b0260","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/604204","article-title":"Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb","volume":"2012","author":"Lallemand","year":"2012","journal-title":"Journal of drug delivery"},{"issue":"6","key":"10.1016\/j.addr.2023.115005_b0265","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcjo.2012.08.019","article-title":"Effects of phytoestrogen supplementation in postmenopausal women with dry eye syndrome: a randomized clinical trial","volume":"47","author":"Scuderi","year":"2012","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0270","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00417-014-2853-6","article-title":"Evaluation of oxidative stress levels in the conjunctival epithelium of patients with or without dry eye, and dry eye patients treated with preservative-free hyaluronic acid 0.15 % and vitamin B12 eye drops","volume":"253","author":"Macri","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0275","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/jop.2010.0025","article-title":"Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation","volume":"26","author":"Davitt","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.addr.2023.115005_b0280","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.2147\/OPTH.S263362","article-title":"Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV","volume":"14","author":"Silverstein","year":"2020","journal-title":"Multicenter Trial, Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0285","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.drudis.2018.11.022","article-title":"The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions","volume":"24","author":"Polamreddy","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"9","key":"10.1016\/j.addr.2023.115005_b0290","article-title":"Pre-clinical efficacy of OCU300 nanoemulsion for the treatment of ocular graft versus host disease (oGVHD)","volume":"59","author":"Arumugham","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2023.115005_b0295","unstructured":"J. D., Z. N., M. P., A phase II randomized, placebo-controlled, double-masked, proof-of-concept study of brimonidine (BRI) eye drops for the treatment of dry eye disease (DED), American Academy of Ophthalmology Annual Meeting, Chicago, IL, 2018."},{"issue":"5","key":"10.1016\/j.addr.2023.115005_b0300","first-page":"564","article-title":"Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized","volume":"40","author":"Korenfeld","year":"2021","journal-title":"Vehicle-Controlled Studies"},{"issue":"1\u20132","key":"10.1016\/j.addr.2023.115005_b0305","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40123-014-0021-z","article-title":"Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation","volume":"3","author":"Schopf","year":"2014","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b0310","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijpharm.2015.12.037","article-title":"Topical delivery of aqueous micellar resolvin E1 analog (RX-10045)","volume":"498","author":"Cholkar","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115005_b0315","unstructured":"N. Kunzevitzky, C. Fleming, J.K. Thoele, R. Goldberg, J.L. Goldberg, Phase 1 Multicenter Study of Magnetic Cell Therapy for Corneal Edema, Investigative Ophthalmology & Visual Science 63(7) (2022) 2758 \u2013 A0247-2758 \u2013 A0247."},{"issue":"10","key":"10.1016\/j.addr.2023.115005_b0320","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","volume":"117","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"27","key":"10.1016\/j.addr.2023.115005_b0325","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.addr.2023.115005_b0330","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/13543784.2022.2052042","article-title":"KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases","volume":"31","author":"Stern","year":"2022","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b0335","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/aos.15215","article-title":"Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double-masked, vehicle-controlled study","volume":"101","author":"Stefansson","year":"2023","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"10.1016\/j.addr.2023.115005_b0340","first-page":"1577","article-title":"OCS-01 (Novel Topical Dexamethasone Formulation) in Inflammation and Pain Post Cataract Surgery: A Randomized","volume":"44","author":"Korenfeld","year":"2022","journal-title":"Double-Masked, Vehicle-Controlled Study, Clin Ther"},{"key":"10.1016\/j.addr.2023.115005_b0345","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jconrel.2021.05.035","article-title":"Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration","volume":"335","author":"Kambhampati","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2023.115005_b0350","unstructured":"J. Cleland, R. Sharma, S. Appiani, J. Moore, B. Rogers, Safety and Tolerability of a Single Subcutaneous Dose of Anti-Angiogenesis Drug to Treat Neovascular Age-related Macular Degeneration (wet AMD) and Diabetic Macular Edema (DME), Investigative Ophthalmology & Visual Science 63(7) (2022) 1347 \u2013 F0181-1347 \u2013 F0181."},{"issue":"7","key":"10.1016\/j.addr.2023.115005_b0355","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/13543784.2016.1181750","article-title":"Investigational drugs for retinal vein occlusion","volume":"25","author":"Bremond-Gignac","year":"2016","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0360","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s13346-014-0196-9","article-title":"Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops","volume":"4","author":"Wong","year":"2014","journal-title":"Drug Deliv. Transl. Res."},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b0365","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2415-10-4","article-title":"First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure","volume":"10","author":"Denis","year":"2010","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.addr.2023.115005_b0370","doi-asserted-by":"crossref","unstructured":"D. ISMAIL, M. AMRANE, J. GARRIGUE, R. BUGGAGE, A phase 2, randomized study evaluating the safety and efficacy of Catioprost\u00ae (unpreserved latanoprost 0.005% emulsion) compared to Travatan Z\u00ae in subjects with glaucoma and ocular surface disease, 89(s248) (2011) 0-0.","DOI":"10.1111\/j.1755-3768.2011.227.x"},{"issue":"6","key":"10.1016\/j.addr.2023.115005_b0375","first-page":"1154","article-title":"An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD","volume":"36","author":"Ghanchi","year":"2022","journal-title":"DMO, RVO, uveitis and glaucoma, Eye"},{"key":"10.1016\/j.addr.2023.115005_b0380","doi-asserted-by":"crossref","unstructured":"J.C.J.A.d.d.r. Lang, Ocular drug delivery conventional ocular formulations, 16(1) (1995) 39-43.","DOI":"10.1016\/0169-409X(95)00012-V"},{"key":"10.1016\/j.addr.2023.115005_b0385","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.partic.2021.05.009","article-title":"Nanoemulsions for drug delivery","volume":"64","author":"Wilson","year":"2022","journal-title":"Particuology"},{"key":"10.1016\/j.addr.2023.115005_b0390","doi-asserted-by":"crossref","unstructured":"P. Liu, G. Chen, J. Zhang, A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives, Molecules (Basel, Switzerland) 27(4) (2022).","DOI":"10.3390\/molecules27041372"},{"issue":"6","key":"10.1016\/j.addr.2023.115005_b0395","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1089\/jop.2020.0022","article-title":"Mucus-Penetrating Particles and the Role of Ocular Mucus as a Barrier to Micro- and Nanosuspensions","volume":"36","author":"Popov","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.addr.2023.115005_b0400","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2017.01.012","article-title":"Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies","volume":"248","author":"Mandal","year":"2017","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0405","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0410","first-page":"2537","article-title":"Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN\u00ae) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study","volume":"260","author":"Deuchler","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"10.1016\/j.addr.2023.115005_b0415","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.115005_b0420","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2147\/DDDT.S295223","article-title":"Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration","volume":"15","author":"Hussain","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.addr.2023.115005_b0425","unstructured":"E. Kahn, C. Patel, M. Priem, J. Iacona, A. Vanslette, E. Wong, C.D. Blizzard, P.K. Jarrett, M. Goldstein, R. Gurses-Ozden, A Safety and Pharmacokinetic Study of a Novel Hydrogel-based Axitinib Intravitreal Implant (OTX-TKI) in Non-Human Primates, Investigative Ophthalmology & Visual Science 63(7) (2022) 297 \u2013 F0100-297 \u2013 F0100."},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0430","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.drudis.2019.05.038","article-title":"Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives","volume":"24","author":"Bordet","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0435","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/febs.16330","article-title":"The blood-retina barrier in health and disease","volume":"290","author":"O'Leary","year":"2023","journal-title":"FEBS J"},{"issue":"6","key":"10.1016\/j.addr.2023.115005_b0440","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archopht.1980.01020031041005","article-title":"Acetazolamide dosage forms in the treatment of glaucoma","volume":"98","author":"Berson","year":"1980","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.addr.2023.115005_b0445","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/archopht.1955.00930020191004","article-title":"Long-term acetazoleamide (diamox) administration in therapy of glaucomas","volume":"54","author":"Becker","year":"1955","journal-title":"AMA Arch Ophthalmol"},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0450","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/archopht.1977.04450080088009","article-title":"Carbonic anhydrase inhibitor side effects","volume":"95","author":"Epstein","year":"1977","journal-title":"Serum chemical analysis, Arch Ophthalmol"},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0455","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/febs.16177","article-title":"Myeloid cells in retinal and brain degeneration","volume":"289","author":"Guo","year":"2022","journal-title":"FEBS J"},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0460","first-page":"2337","volume":"289","author":"Guo","year":"2022","journal-title":"Myeloid cells in retinal and brain degeneration"},{"issue":"9","key":"10.1016\/j.addr.2023.115005_b0465","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.drudis.2022.05.024","article-title":"Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases","volume":"27","author":"Bohley","year":"2022","journal-title":"Drug Discov Today"},{"issue":"50","key":"10.1016\/j.addr.2023.115005_b0470","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/20\/50\/505101","article-title":"Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity","volume":"20","author":"Kim","year":"2009","journal-title":"Nanotechnology"},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0475","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1167\/iovs.15-17934","article-title":"Albumen Transport to Bruch's Membrane and RPE by Choriocapillaris Caveolae","volume":"57","author":"Nakanishi","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.addr.2023.115005_b0480","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.exer.2016.08.008","article-title":"AMD-like retinopathy associated with intravenous iron","volume":"151","author":"Song","year":"2016","journal-title":"Exp Eye Res"},{"issue":"7","key":"10.1016\/j.addr.2023.115005_b0485","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bbagen.2008.11.001","article-title":"Iron homeostasis and eye disease","volume":"1790","author":"Loh","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/j.addr.2023.115005_b0490","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.preteyeres.2007.07.004","article-title":"Iron homeostasis and toxicity in retinal degeneration","volume":"26","author":"He","year":"2007","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"10.1016\/j.addr.2023.115005_b0495","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1167\/iovs.05-1135","article-title":"The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration","volume":"47","author":"Chowers","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.addr.2023.115005_b0500","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/gt.2008.185","article-title":"Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV","volume":"16","author":"Singh","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/j.addr.2023.115005_b0505","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejps.2014.04.018","article-title":"Topical drug delivery to retinal pigment epithelium with microfluidizer produced small liposomes","volume":"62","author":"Lajunen","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"10.1016\/j.addr.2023.115005_b0510","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1006\/exer.2001.0998","article-title":"Glutathione transport in human retinal pigment epithelial (HRPE) cells: apical localization of sodium-dependent gsh transport","volume":"72","author":"Kannan","year":"2001","journal-title":"Exp Eye Res"},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0515","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1167\/iovs.13-13599","article-title":"Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation","volume":"55","author":"Reijerkerk","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.addr.2023.115005_b0520","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/bcp.13525","article-title":"Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study","volume":"84","author":"Kanhai","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0525","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jconrel.2012.06.022","article-title":"Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation","volume":"164","author":"Gaillard","year":"2012","journal-title":"J Control Release"},{"issue":"12","key":"10.1016\/j.addr.2023.115005_b0530","first-page":"4197","article-title":"Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and","volume":"21","author":"Buck","year":"2020","journal-title":"Transgene Expression and Bioactivity Assays"},{"issue":"10","key":"10.1016\/j.addr.2023.115005_b0535","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.7150\/thno.15230","article-title":"Cell-Specific Promoters Enable Lipid-Based Nanoparticles to Deliver Genes to Specific Cells of the Retina In Vivo","volume":"6","author":"Wang","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2023.115005_b0540","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.addr.2017.12.008","article-title":"Implications of melanin binding in ocular drug delivery","volume":"126","author":"Rimpela","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.addr.2023.115005_b0545","first-page":"405","article-title":"The Reaction of Uveal Pigment in Vitro with Polycyclic Compounds","volume":"3","author":"Potts","year":"1964","journal-title":"Invest Ophthalmol"},{"issue":"7101","key":"10.1016\/j.addr.2023.115005_b0550","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(59)90604-X","article-title":"Retinopathy following chloroquine therapy","volume":"2","author":"Hobbs","year":"1959","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0555","first-page":"671","article-title":"An explanation for the long duration of mydriatic effect of atropine in eye","volume":"15","author":"Salazar","year":"1976","journal-title":"Invest Ophthalmol"},{"issue":"5","key":"10.1016\/j.addr.2023.115005_b0560","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0002-9394(71)91689-8","article-title":"Effect of ocular pigmentation on hypotensive response to pilocarpine","volume":"72","author":"Harris","year":"1971","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b0565","first-page":"32","article-title":"Binding of antiglaucomatous drugs to synthetic melanin and their hypotensive effects on pigmented and nonpigmented rabbit eyes","volume":"37","author":"Nagata","year":"1993","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b9000","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1038\/s41467-023-38056-w","article-title":"Machine learning-driven multifunctional peptide engineering for sustained ocular drug delivery","volume":"14","author":"Hsueh","year":"2023","journal-title":"Nat Commun."},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0570","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s13346-021-00987-6","article-title":"A hypotonic gel-forming eye drop provides enhanced intraocular delivery of a kinase inhibitor with melanin-binding properties for sustained protection of retinal ganglion cells","volume":"12","author":"Kim","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"12","key":"10.1016\/j.addr.2023.115005_b0575","doi-asserted-by":"crossref","first-page":"e0144341","DOI":"10.1371\/journal.pone.0144341","article-title":"Synapse Loss and Dendrite Remodeling in a Mouse Model of Glaucoma","volume":"10","author":"Berry","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.addr.2023.115005_b0580","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1364\/BOE.4.000364","article-title":"Imaging axonal transport in the rat visual pathway","volume":"4","author":"Abbott","year":"2013","journal-title":"Biomed Opt Express"},{"key":"10.1016\/j.addr.2023.115005_b0585","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.actbio.2021.03.043","article-title":"Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model","volume":"126","author":"Ding","year":"2021","journal-title":"Acta Biomater"},{"issue":"12","key":"10.1016\/j.addr.2023.115005_b0590","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1021\/acs.molpharmaceut.9b01046","article-title":"How Nanoparticle Physicochemical Parameters Affect Drug Delivery to Cells in the Retina via Systemic Interactions","volume":"16","author":"You","year":"2019","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0595","first-page":"427","article-title":"Liposomal benzoporphyrin derivative verteporfin photodynamic therapy","volume":"103","author":"Kramer","year":"1996","journal-title":"Selective treatment of choroidal neovascularization in monkeys, Ophthalmology"},{"issue":"6","key":"10.1016\/j.addr.2023.115005_b0600","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/archopht.1995.01100060136048","article-title":"Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin","volume":"113","author":"Miller","year":"1995","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0605","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0039-6257(00)00158-2","article-title":"Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration","volume":"45","author":"Schmidt-Erfurth","year":"2000","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"10.1016\/j.addr.2023.115005_b0610","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archopht.122.7.1002","article-title":"Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2","volume":"122","author":"Renno","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b0615","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/s41467-019-08690-4","article-title":"Intravenous treatment of choroidal neovascularization by photo-targeted nanoparticles","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2023.115005_b0620","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2015.01.001","article-title":"Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye","volume":"200","author":"Huu","year":"2015","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.addr.2023.115005_b0625","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1517\/17425247.2010.490554","article-title":"Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach","volume":"7","author":"Campbell","year":"2010","journal-title":"Expert Opin Drug Deliv"},{"issue":"42","key":"10.1016\/j.addr.2023.115005_b0630","doi-asserted-by":"crossref","first-page":"17817","DOI":"10.1073\/pnas.0908561106","article-title":"An experimental platform for systemic drug delivery to the retina","volume":"106","author":"Campbell","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0635","doi-asserted-by":"crossref","first-page":"e1500472","DOI":"10.1126\/sciadv.1500472","article-title":"Autoregulated paracellular clearance of amyloid-beta across the blood-brain barrier","volume":"1","author":"Keaney","year":"2015","journal-title":"Sci Adv"},{"issue":"13","key":"10.1016\/j.addr.2023.115005_b0640","doi-asserted-by":"crossref","first-page":"E2997","DOI":"10.1073\/pnas.1718792115","article-title":"Combination of cGMP analogue and drug delivery system provides functional protection in hereditary retinal degeneration","volume":"115","author":"Vighi","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5\u20136","key":"10.1016\/j.addr.2023.115005_b0645","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.drudis.2010.01.009","article-title":"Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications","volume":"15","author":"Menjoge","year":"2010","journal-title":"Drug Discov Today"},{"issue":"130","key":"10.1016\/j.addr.2023.115005_b0650","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003162","article-title":"Dendrimer-Based Postnatal Therapy for Neuroinflammation and Cerebral Palsy in a Rabbit Model","volume":"4","author":"Kannan","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2023.115005_b0655","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.biomaterials.2015.02.053","article-title":"Uniform brain tumor distribution and tumor associated macrophage targeting of systemically administered dendrimers","volume":"52","author":"Zhang","year":"2015","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0660","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1021\/nn404872e","article-title":"Dendrimer Brain Uptake and Targeted Therapy for Brain Injury in a Large Animal Model of Hypothermic Circulatory Arrest","volume":"8","author":"Mishra","year":"2014","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0665","doi-asserted-by":"crossref","first-page":"e0154437","DOI":"10.1371\/journal.pone.0154437","article-title":"Dendrimers Target the Ischemic Lesion in Rodent and Primate Models of Nonarteritic Anterior Ischemic Optic Neuropathy","volume":"11","author":"Guo","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0670","first-page":"eaay8514","article-title":"Dense hydroxyl polyethylene glycol dendrimer targets activated glia in multiple CNS disorders, Science","volume":"6","author":"Sharma","year":"2020","journal-title":"Advances"},{"key":"10.1016\/j.addr.2023.115005_b0675","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.addr.2019.02.009","article-title":"Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders","volume":"148","author":"Smith","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.addr.2023.115005_b0680","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7150\/ntno.63158","article-title":"Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis","volume":"6","author":"Hollinger","year":"2022","journal-title":"Nanotheranostics"},{"issue":"12","key":"10.1016\/j.addr.2023.115005_b0685","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1517\/17425247.2013.853661","article-title":"Poly(amidoamine) dendrimer complexes as a platform for gene delivery","volume":"10","author":"Shcharbin","year":"2013","journal-title":"Expert Opin Drug Deliv"},{"issue":"7","key":"10.1016\/j.addr.2023.115005_b0690","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215308120","article-title":"Dendrimer nanosystems for adaptive tumor-assisted drug delivery via extracellular vesicle hijacking","volume":"120","author":"Jiang","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.addr.2023.115005_b0695","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1021\/acs.bioconjchem.0c00395","article-title":"Dendrimers toward Translational Nanotherapeutics: Concise Key Step Analysis","volume":"31","author":"Mignani","year":"2020","journal-title":"Bioconjug Chem"},{"issue":"13","key":"10.1016\/j.addr.2023.115005_b0700","doi-asserted-by":"crossref","DOI":"10.3390\/polym14132684","article-title":"Polyglycerols as Multi-Functional Platforms: Synthesis and Biomedical Applications","volume":"14","author":"Pouyan","year":"2022","journal-title":"Polymers (Basel)"},{"issue":"7","key":"10.1016\/j.addr.2023.115005_b0705","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1039\/C1CS15242D","article-title":"Multifunctional dendritic polymers in nanomedicine: opportunities and challenges","volume":"41","author":"Khandare","year":"2012","journal-title":"Chem Soc Rev"},{"issue":"9","key":"10.1016\/j.addr.2023.115005_b0710","article-title":"Design, Synthetic Strategies, and Therapeutic Applications of Heterofunctional Glycodendrimers, Molecules (Basel","volume":"26","author":"Mousavifar","year":"2021","journal-title":"Switzerland)"},{"issue":"81","key":"10.1016\/j.addr.2023.115005_b0715","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002212","article-title":"A Phosphorus-Based Dendrimer Targets Inflammation and Osteoclastogenesis in Experimental Arthritis","volume":"3","author":"Hayder","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"21","key":"10.1016\/j.addr.2023.115005_b0720","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.2174\/1381612823666170309151958","article-title":"Dendrimers Effects on the Immune System: Insights into Toxicity and Therapeutic Utility","volume":"23","author":"Dobrovolskaia","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b0725","doi-asserted-by":"crossref","first-page":"9410","DOI":"10.1038\/s41598-018-27400-6","article-title":"PEGylation of polypropylenimine dendrimers: effects on cytotoxicity, DNA condensation, gene delivery and expression in cancer cells","volume":"8","author":"Somani","year":"2018","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0730","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12081334","article-title":"Dendrimers, an Emerging Opportunity in Personalized Medicine?","volume":"12","author":"Caminade","year":"2022","journal-title":"J Pers Med"},{"issue":"654","key":"10.1016\/j.addr.2023.115005_b0735","doi-asserted-by":"crossref","first-page":"eabo2652","DOI":"10.1126\/scitranslmed.abo2652","article-title":"Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial","volume":"14","author":"Gusdon","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b0740","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","article-title":"Design and optimisation of dendrimer-conjugated Bcl-2\/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy","volume":"4","author":"Patterson","year":"2021","journal-title":"Communications Biology"},{"issue":"7","key":"10.1016\/j.addr.2023.115005_b0745","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41578-022-00426-z","article-title":"Design of therapeutic biomaterials to control inflammation","volume":"7","author":"Tu","year":"2022","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.addr.2023.115005_b0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113456","article-title":"First-in-class and best-in-class dendrimer nanoplatforms from concept to clinic: Lessons learned moving forward","volume":"219","author":"Mignani","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.addr.2023.115005_b0755","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1039\/C5CS00288E","article-title":"The dendrimer paradox\u2013high medical expectations but poor clinical translation","volume":"44","author":"Svenson","year":"2015","journal-title":"Chem Soc Rev"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0760","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/mp2005033","article-title":"Exploiting dendrimer multivalency to combat emerging and re-emerging infectious diseases","volume":"9","author":"Mintzer","year":"2012","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0765","article-title":"Dendrimer-targeted immunosuppression of microglia reactivity super-accelerates photoreceptor regeneration kinetics in the zebrafish retina","volume":"62","author":"Emmerich","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"20","key":"10.1016\/j.addr.2023.115005_b0770","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.7150\/thno.29039","article-title":"Targeting Mitochondrial Dysfunction and Oxidative Stress in Activated Microglia using Dendrimer-Based Therapeutics","volume":"8","author":"Sharma","year":"2018","journal-title":"Theranostics"},{"issue":"41","key":"10.1016\/j.addr.2023.115005_b0775","doi-asserted-by":"crossref","first-page":"46290","DOI":"10.1021\/acsami.2c13129","article-title":"Dendrimer\u2013siRNA Conjugates for Targeted Intracellular Delivery in Glioblastoma Animal Models","volume":"14","author":"Liyanage","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.addr.2023.115005_b0780","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12974-016-0529-3","article-title":"Microglial migration and interactions with dendrimer nanoparticles are altered in the presence of neuroinflammation","volume":"13","author":"Zhang","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.addr.2023.115005_b0785","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.biomaterials.2016.05.044","article-title":"Nanoscale effects in dendrimer-mediated targeting of neuroinflammation","volume":"101","author":"Nance","year":"2016","journal-title":"Biomaterials"},{"issue":"13","key":"10.1016\/j.addr.2023.115005_b0790","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.7150\/thno.41714","article-title":"Dendrimer-conjugated glutaminase inhibitor selectively targets microglial glutaminase in a mouse model of Rett syndrome","volume":"10","author":"Khoury","year":"2020","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.addr.2023.115005_b0795","doi-asserted-by":"crossref","first-page":"e10160","DOI":"10.1002\/btm2.10160","article-title":"Dendrimer size effects on the selective brain tumor targeting in orthotopic tumor models upon systemic administration","volume":"5","author":"Liaw","year":"2020","journal-title":"Bioeng. Transl. Med."},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0800","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.biomaterials.2011.10.010","article-title":"Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration","volume":"33","author":"Iezzi","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.115005_b0805","unstructured":"R.I. Kannan Rangaramanujam, Bharath Rajaguru, Sujatha Kannan, Dendrimers for sustained release of compounds, US Patent 10463609B2, USA, 2008."},{"issue":"2","key":"10.1016\/j.addr.2023.115005_b0810","article-title":"Dendrimer-Triamcinolone Acetonide Reduces Neuroinflammation, Pathological","volume":"4","author":"Cho","year":"2021","journal-title":"Angiogenesis"},{"issue":"3","key":"10.1016\/j.addr.2023.115005_b0815","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1021\/acs.biomac.2c01381","article-title":"Targeted Microglial Attenuation through Dendrimer-Drug Conjugates Improves Glaucoma Neuroprotection","volume":"24","author":"Pitha","year":"2023","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2023.115005_b0820","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejpb.2015.02.013","article-title":"Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells","volume":"95","author":"Kambhampati","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115005_b0825","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.biomaterials.2017.02.016","article-title":"Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation","volume":"125","author":"Soiberman","year":"2017","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.addr.2023.115005_b0830","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1167\/iovs.13-13650","article-title":"Ocular Pharmacokinetics of Intravitreally Administered Brimonidine and Dexamethasone in Animal Models With and Without Blood-Retinal Barrier Breakdown","volume":"55","author":"Shen","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.addr.2023.115005_b0835","doi-asserted-by":"crossref","first-page":"e00545","DOI":"10.1002\/prp2.545","article-title":"Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys","volume":"7","author":"Horita","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"10.1016\/j.addr.2023.115005_b0840","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1167\/iovs.16-19204","article-title":"Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model","volume":"57","author":"Park","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.addr.2023.115005_b0845","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1167\/iovs.14-16250","article-title":"Systemic and Intravitreal Delivery of Dendrimers to Activated Microglia\/Macrophage in Ischemia\/Reperfusion Mouse Retina","volume":"56","author":"Kambhampati","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.addr.2023.115005_b0850","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.ophtha.2010.03.033","article-title":"Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application","volume":"117","author":"Shen","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.addr.2023.115005_b0855","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1600-0420.2007.00885.x","article-title":"Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye","volume":"85","author":"Sigurdsson","year":"2007","journal-title":"Acta Ophthalmol. Scand."},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0860","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00006982-200506000-00017","article-title":"Suppression of laser-induced choroidal neovascularization by posterior sub-tenon administration of triamcinolone acetonide","volume":"25","author":"Kato","year":"2005","journal-title":"Retina"},{"key":"10.1016\/j.addr.2023.115005_b0865","series-title":"Dendrimer compositions for use in angiography","author":"Kannan Rangaramanujam","year":"2018"},{"key":"10.1016\/j.addr.2023.115005_b0870","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.16-20049","volume":"57","author":"McLeod","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"10","key":"10.1016\/j.addr.2023.115005_b0875","article-title":"Macroglia-Microglia Interactions via TSPO Signaling Regulates Microglial Activation in the Mouse Retina","volume":"34","author":"Minhua Wang","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.addr.2023.115005_b0880","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.preteyeres.2014.11.004","author":"Karlstetter","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2023.115005_b0885","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1167\/iovs.03-0097","volume":"44","author":"Sakurai","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2023.115005_b0890","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.preteyeres.2005.01.004","volume":"24","author":"Jonas","year":"2005","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2023.115005_b0895","unstructured":"C.C.W. P.A. Campochiaro, D.M. Brown, D.S. Boyer, M. Barakat, D. Taraborelli, G. Noronha, T.S., Group, Ophthalmology Retina (2017)."},{"issue":"4","key":"10.1016\/j.addr.2023.115005_b0900","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11051-018-4219-1","article-title":"Quantitative assessment of surface functionality effects on microglial uptake and retention of PAMAM dendrimers","volume":"20","author":"Liaw","year":"2018","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.addr.2023.115005_b0905","unstructured":"Unpublished. https:\/\/avttx.com\/pipeline\/ophthalmology."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23003204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23003204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:37:02Z","timestamp":1759210622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X23003204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":182,"alternative-id":["S0169409X23003204"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2023.115005","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new era in posterior segment ocular drug delivery: Translation of systemic, cell-targeted, dendrimer-based therapies","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2023.115005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115005"}}